Abbott Laboratories’ (ABT) “Buy” Rating Reiterated at TD Cowen

TD Cowen restated their buy rating on shares of Abbott Laboratories (NYSE:ABT) in a report published on Tuesday,Benzinga reports. They currently have a $135.00 target price on the healthcare product maker’s stock.

Several other research firms also recently weighed in on ABT. JPMorgan Chase & Co. lifted their target price on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Citigroup lifted their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday, July 17th. BTIG Research boosted their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Robert W. Baird started coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price on the stock. Finally, Bank of America reduced their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Abbott Laboratories Stock Down 1.8%

Shares of NYSE ABT opened at $103.37 on Tuesday. The company has a market cap of $178.87 billion, a P/E ratio of 33.45, a PEG ratio of 1.95 and a beta of 0.59. The firm has a 50-day simple moving average of $105.46 and a two-hundred day simple moving average of $99.84. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same period in the prior year, the business posted $1.26 earnings per share. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Cornerstone Financial Management LLC bought a new position in Abbott Laboratories in the fourth quarter worth approximately $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories in the fourth quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in Abbott Laboratories during the fourth quarter worth $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories during the 4th quarter valued at $26,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.